News & Resources

Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32 (naltrexone sustained release (SR) / bupropion SR). Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company hasMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$5.70
Change (%) Stock is Down 0.03 (0.52%)
Volume4,158,919
Aug 29, 2014 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
08/07/14Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014Printer Friendly Version
07/31/14Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and WebcastPrinter Friendly Version
07/30/14Orexigen Receives CHMP Day 180 List of Outstanding IssuesPrinter Friendly Version
06/13/14Orexigen Therapeutics to Present at the Wells Fargo Securities 2014 Healthcare ConferencePrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.